Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 18.25
Low: 18.00
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Wed, 06th Jan 2021 14:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

River & Mercantile Group PLC - Hires Martin Gilbert to be deputy chair, starting Wednesday. Gilbert was the co-founder and then chief executive of Aberdeen Asset Management, now Standard Life Aberdeen PLC. He currently is chair of lender Revolut Ltd and senior independent director of miner Glencore PLC. "In the current environment there are market opportunities for RMG, both organic and through acquisitions, that can drive shareholder value," Gilbert says. River & Mercantile had GBP45.4 billion in assets under management as of September 30.

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Daren Harris steps down as chief executive officer and from board, effective immediately. Chief Operating Officer Terry Dugdale, in post since March 2019, becomes CEO. "The business is well placed with strong market drivers and a robust balance sheet and its strategy is strongly positioned to capitalise on the UK's journey to net zero," Harris says. "Unfortunately, due to personal reasons, I need to step down from the business." He adds: "Since joining the business, Terry has driven our operating efficiency and has made significant progress in preparing the business foundations for the future."

----------

Silence Therapeutics PLC - London-based novel short interfering ribonucleic acid therapeutics developer - Hires Craig Tooman as chief financial officer, effective immediately. Tooman was most recently CFO & COO of Princeton, New Jersey-based Vyome Therapeutic Inc. Silence also says Michael Davidson has joined the Silence board as non-executive director. Davidson currently is CEO of New Amsterdam Pharma BV and a professor of medicine at the Lipid Clinic at the University of Chicago. He founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca PLC in 2013, and was founding CEO of Corvidia Therapeutics, which was acquired by Novo Nordisk AS in 2020.

----------

Personal Group Holdings PLC - Milton Keynes, Buckinghamshire-based provider of employee services - Makes Interim CFO Sarah Mace its permanent CFO, effective immediately. Mace was promoted to the board as interim CFO back in October, having joined Personal Group in 2014.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software company - Hires Pierre-Etienne Lallia as non-executive director, effective immediately. Lallia spent 10 years at Nomura International PLC in London, where he was managing director of the Acquisition & Leveraged Finance team. Prior to that, he was with Goldman Sachs International, part of Goldman Sachs Group Inc.

----------

Time Finance PLC - Bath, England-based finance provider to UK small and medium businesses - Non-Executive Chair John Newman and CEO Ian Smith both to retire once successors are found. Says process for replacing the pair is underway. Says Smith's decision follows rebranding of company from 1pm PLC early last month and his previous intention to retire in any event at the end of 2021.

----------

Destiny Pharma PLC - Brighton-based clinical stage biotechnology firm focused on preventing infections - Hires Stephanie Bewick as chief business officer. Bewick was vice president for Business Development at Nasdaq-listed Summit Therapeutics Inc.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
27 May 2021 16:06

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Apr 2021 12:04

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

Read more
7 Apr 2021 15:58

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
29 Mar 2021 09:59

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Read more
29 Mar 2021 09:02

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Destiny Pharma jumps as infection-fighting nasal gel shows promise

Read more
15 Mar 2021 21:44

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge

Read more
10 Mar 2021 20:22

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

IN BRIEF: Destiny Pharma CSO joins UK Covid-19 research taskforce

Read more
3 Feb 2021 11:09

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

IN BRIEF: Destiny Pharma Secures Brazilian Patent For XF-73 Nasal Gel

Read more
2 Feb 2021 14:34

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

IN BRIEF: Destiny Pharma Adds Mark Wilcox To Scientific Advisory Board

Read more
5 Jan 2021 21:15

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

IN BRIEF: Destiny Pharma Completes Recruitment For XF-73 Gel Trial

Read more
5 Jan 2021 11:21

Destiny Pharma meets recruitment deadline for XF-73 trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Tuesday that its XF-73 phase 2b clinical trial was fully recruited by 31 December, meeting the target timeline set for the programme.

Read more
22 Dec 2020 18:06

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

UK TRADING UPDATE SUMMARY: Lekoil Fires Back At Shareholder Metallon

Read more
25 Nov 2020 18:00

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

UK TRADING UPDATE SUMMARY: SourceBio Tips Jump In Virus Testing Demand

Read more
9 Nov 2020 17:15

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Destiny Pharma Set For GBP11.5 Million Raise To Buy NTCD-M3

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.